Eikonoklastes Therapeutics is developing a pipeline of disruptive new therapies that we can rapidly and relatively inexpensively advance from preclinical stage to clinical proof-of-concept and approval. We have now acquired our first two assets to treat devastating diseases that currently are severely inadequately treated. Our focus is on novel compounds that: 1) have platform capability where one molecule can treat multiple diseases with severe unmet clinical need, 2) will get preferred regulatory treatment due to the high unmet need and breakthrough potential, and 3) need relatively small clinical trials to achieve approval. Our 1st in class gene therapy (ET-101) has been engineered to overexpress Caveolin-1, which organizes & regulates synaptic receptors essential for neuromuscular signaling and function. It can treat a wide range of neurodegenerative diseases through precise, targeted overexpression of Caveolin-1 in neurons . We are also advancing a new generation of tissue factor (TF) therapies (ET-201) – therapeutics designed to target the cell surface receptor now known to be prevalent on solid tumor cells, tumor vasculature, and tumor stem cells, but absent on normal cells. By targeting these proteins which play a central role in the pathology of inflammation and angiogenesis, we can stop tumor growth, spread, and recurrence. Our first indications are neurodegenerative diseases and cancers with high unmet need and high mortality (e.g. ALS and triple negative breast cancer). A robust pipeline of additional indications (e.g. Alzheimer’s, Parkinson’s, etc. for ET-101; ovarian cancer, melanoma, etc. for ET-201) with severely inadequate treatment options will subsequently be pursued with these therapeutics.